<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121120</url>
  </required_header>
  <id_info>
    <org_study_id>TXA127-2009-001</org_study_id>
    <nct_id>NCT01121120</nct_id>
  </id_info>
  <brief_title>Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients</brief_title>
  <acronym>TXA127-PBSC</acronym>
  <official_title>Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tarix Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tarix Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of TXA127 in
      accelerating the time it takes for patients to recover their platelet counts following a
      Autologous Peripheral Blood Stem Cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  This is a randomized, double-blind (Investigator and Study Subject), placebo-controlled
           study.

        -  The conditioning regimen and mobilization agents used will be up to the discretion of
           the Study Center Investigator
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet recovery</measure>
    <time_frame>≤ 28 days from re-infusion of CD34+ cells</time_frame>
    <description>Evaluate the effectiveness of TXA127 in accelerating the time to initial platelet recovery following PBSC transplant with a limited number of CD34+ cells, defined as CD34+ cell concentrations ≥1.5 x 106 and ≤5.0 x 106 CD34+ cells/kg. Platelet recovery is defined as that day the subject achieves a post-nadir platelet count of ≥20 x 109/L with no platelet transfusion in the prior 7 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of TXA127</measure>
    <time_frame>≤ 28 days from re-infusion of CD34+ cells</time_frame>
    <description>Evaluate the safety of TXA127 administration following PBSC transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial neutrophil recovery</measure>
    <time_frame>≤ 28 days from re-infusion of CD34+ cells</time_frame>
    <description>Determine the effectiveness of TXA127 in accelerating the days to initial neutrophil recovery (ANCs &gt; 0.5 x 10⁹/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucositis</measure>
    <time_frame>≤ 28 days from re-infusion of CD34+ cells</time_frame>
    <description>Evaluate the incidence of mucositis Grade 3/4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Febrile neutropenia</measure>
    <time_frame>≤ 28 days from re-infusion of CD34+ cells</time_frame>
    <description>Evaluate the effect of TXA127 in reducing the number of days of febrile neutropenia (fever and ANC &lt;0.5 x 109/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet transfusions</measure>
    <time_frame>≤ 28 days from re-infusion of CD34+ cells</time_frame>
    <description>Evaluate the effect of TXA127 in reducing the number of platelet transfusions needed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Hodgkin Disease</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>TXA127</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mcg/kg/day administered subcutaneously up to 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>300mcg/kg/day administered subcutaneously up to 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TXA127</intervention_name>
    <description>300mcg/kg/day, administered subcutaneously for up to 28 days</description>
    <arm_group_label>TXA127</arm_group_label>
    <other_name>Angiotensin 1-7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>300mcg/kg/day administered subcutaneously for up to 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be at least 18 years of age

          -  Subjects must have HL, NHL, or MM requiring PBSCT

          -  Subjects must have a life expectancy of at least 4 months

          -  Subjects are to receive autologous PBSC transplant following mobilization, CD34+ cells
             collected by apheresis, and conditioning chemotherapy

          -  Subjects must give written informed consent to participate in study. Consent must be
             obtained prior to the performance of any study-specific, non-institutional standard
             procedures. A copy of the signed informed consent will be retained in the subject's
             chart.

          -  Subjects must have CD34+ collection which allows reinfusion of ≥1.5 x 106 and ≤5.0 x
             106 CD34+ cells/kg

          -  Subjects must have a psychological and emotional state that, in the view of the
             investigators, allows adherence to the protocol

          -  Female subjects capable of reproduction, and male subjects who have partners capable
             of reproduction, must agree to the following:

               -  Use of an effective contraceptive method during the course of the study and for 2
                  months following the last administration of Investigational Product

               -  Female subjects capable of reproduction must have a negative beta human chorionic
                  gonadotropin (BHCG) serum or urine pregnancy test result within 7 days prior to
                  first Investigational Product dose

               -  Female subjects who are surgically sterilized or who have not experienced menses
                  for at least two years are not required to have a pregnancy test

        Exclusion Criteria:

          -  Subjects who have received radiotherapy to the pelvis and/or sternum within one year
             of first Investigational Product administration

          -  Subjects who have previously received or have planned Total Body Irradiation (TBI)

          -  Subjects with a history of prior malignancy other than HL, NHL, or MM that have not
             been in remission for &gt;5 years, with the exception of basal cell or squamous cell
             carcinoma, cervical carcinoma in situ on biopsy, or localized prostate cancer (Gleason
             score &lt;5)

          -  Subjects with a history of myelodysplastic syndrome

          -  Subjects who have had a venous or arterial embolic event AND who have received
             anti-coagulant treatment, where both the event and the treatment were within six
             months of the first Investigational Product administration

          -  Prior allogeneic hematopoietic cell transplant

          -  Presence of an uncontrolled infection or infection that required intravenous treatment
             within 7 days of entry

          -  Female subjects who are pregnant or breastfeeding

          -  Subjects who have received treatment with an investigational agent within 30 days of
             the projected first administration of Investigational Product (Day 0)

          -  Subjects with current alcohol use, illicit drug use, or any other condition (e.g.,
             psychiatric disorder) that, in the opinion of the Investigator, may interfere with the
             subject's ability to comply with the study requirements or visit schedule

          -  Subjects with a known sensitivity to any of the Investigational Product components

          -  Subjects known to be seropositive for HIV or for HTLV-I

          -  Subjects for whom prophylactic platelet transfusions, at platelet counts &gt;10× 109/L,
             are anticipated following PBSC transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Schuster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stony Brook university Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Hospital</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook</name>
      <address>
        <city>Long Island City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiori Medical Center</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2010</study_first_submitted>
  <study_first_submitted_qc>May 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma, Non-Hodgkin</keyword>
  <keyword>Hodgkin Disease</keyword>
  <keyword>Multiple myeloma</keyword>
  <keyword>Peripheral Blood Stem Cell Transplant</keyword>
  <keyword>Autologous Peripheral Blood Stem Cell Transplant</keyword>
  <keyword>Limited re-infusion of CD34+ cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

